Main Uses and Benefits of Ulcezol

Ulcezol is a medication belonging to the class of proton pump inhibitors (PPIs). It is primarily used to manage conditions characterized by excessive gastric acid production. By reducing the amount of acid secreted by the stomach lining, it allows the digestive tract to heal and prevents further irritation.

Treatment of Acid-Related Disorders

The medication is commonly used for the following conditions:

• Gastroesophageal Reflux Disease (GERD): Ulcezol helps alleviate symptoms such as heartburn and acid regurgitation by preventing stomach acid from rising into the esophagus.
• Gastric and Duodenal Ulcers: It promotes the healing of open sores that develop on the inner lining of the stomach or the upper part of the small intestine.
• Erosive Esophagitis: The reduction in acid levels assists in repairing damage to the esophagus caused by chronic acid reflux.
• Zollinger-Ellison Syndrome: It is used to manage rare conditions where the stomach produces abnormally high amounts of acid due to certain growths.

Benefits of Acid Reduction

Reducing gastric acid production provides several clinical benefits for patients with digestive health concerns:

• Symptom Relief: Effective management of burning sensations in the chest and throat, as well as abdominal discomfort.
• Tissue Recovery: By creating a less acidic environment, the medication facilitates the natural repair process of the mucosal lining in the stomach and esophagus.
• Prevention of Complications: Consistent management of acid levels can reduce the risk of long-term damage, such as the narrowing of the esophagus or the recurrence of ulcers.

Population Eligibility for Ulcezol (Omeprazole)

Official regulatory documents define specific populations who can and cannot use Ulcezol based on eligibility, contraindications, and conditional use.

Absolute Contraindications

Ulcezol must not be used by patients with a known hypersensitivity to the active substance, omeprazole, or to any substituted benzimidazoles (the drug’s chemical class). Additionally, Ulcezol is contraindicated in patients receiving concomitant treatment with the antiretroviral medication Nelfinavir.

Age-Specific Eligibility

Use is established for adults and for pediatric patients 1 year of age and older for specific approved indications, such as symptomatic Gastroesophageal Reflux Disease (GERD). Safety and efficacy are not established for use in infants younger than 1 month of age. Older adults (65+ years) are eligible and typically do not require dose adjustment based on age alone.

Conditional Use

Patients with severe hepatic impairment are eligible but may require a lower daily dose due to altered drug clearance, indicating a restriction on the standard maximum dosage. Conversely, patients with renal impairment generally do not require dose adjustments. Regulators also emphasize the need to exclude gastric malignancy before starting therapy, as symptom relief may delay diagnosis.

Ulcezol Interactions with other medicines and products — Official Regulatory Information

The interaction profile of Ulcezol is primarily defined by its effects on gastric acid levels and its activity as a metabolic enzyme inhibitor, leading to several documented restrictions and monitoring requirements.

Interaction Classification	Relevant Substances/Conditions
Contraindicated or Avoided Combinations	Co-administration with Rilpivirine-containing products is formally contraindicated. Concomitant use with Clopidogrel, Atazanavir, Nelfinavir, the herbal product St John's Wort, and Rifampin is specifically advised against by regulatory authorities.
Exposure-Altering Interactions	Ulcezol may prolong the elimination and increase the exposure of certain medicines metabolized by the CYP2C19 enzyme, including Warfarin, Phenytoin, Diazepam, and Cilostazol. Ulcezol may also increase the plasma levels of Digoxin and Tacrolimus.
pH-Dependent Absorption	By reducing gastric acid, Ulcezol may interfere with the absorption of products that require an acidic environment for bioavailability, such as Iron salts, Ketoconazole, and Ampicillin esters.
Diagnostic & Procedural Constraints	Ulcezol use must be temporarily discontinued for at least 14 days before measurements of Chromogranin A (CgA), as the medication can falsely elevate test results for neuroendocrine tumors.

Co-administration with enzyme inducers such as Rifampin or St John's Wort is avoided because they may reduce Ulcezol's concentration. Additionally, notes exist in official documents regarding heightened Ulcezol exposure in populations identified as CYP2C19 poor metabolizers and in patients with hepatic impairment.

How Ulcezol Works

Ulcezol, a small molecule classified as a Proton Pump Inhibitor (PPI), exerts its action by modulating the enzyme system responsible for gastric acid transport.

---

Irreversible Blockade of the H^+/ K^+-ATPase

The drug's primary action is the irreversible, covalent binding to the H^+/ K^+-ATPase enzyme, commonly referred to as the proton pump, which is situated on the secretory surface of the stomach's parietal cells. This interaction prevents the catalytic activity that constitutes the final step of acid secretion, regardless of upstream activation signals. This irreversible inhibition results in a substantial decrease in the rate of hydrogen ion ( H^+) transport, altering the pH within the gastric lumen.

---

pH-Dependent Activation and Targeted Pathway Engagement

Ulcezol is administered as an inactive prodrug that undergoes conversion into its active inhibitory form exclusively within the highly acidic environment of the parietal cell canaliculi. This pH-dependent transformation allows the active compound to accumulate at the site of acid production, resulting in selective inhibition that modulates the signaling dynamics of the H^+/ K^+-ATPase.

Administration Guidelines

Ulcezol (Omeprazole) is primarily administered via the oral route using delayed-release capsules or tablets, which are supplied in strengths including 10 mg, 20 mg, and 40 mg. An intravenous (IV) preparation is available for use in clinical settings when oral intake is temporarily not possible.

The medicine is typically taken once daily and must be consumed before eating, such as prior to breakfast. For most acute conditions, including treatment of Erosive Esophagitis, the prescribed schedule is a standard dose of 20 mg once daily, often continuing for a fixed, short-term course of 4 to 8 weeks. Higher total doses, such as those required for Pathological Hypersecretory Conditions, may be administered in divided doses.

Procedural and Population Requirements

A critical administration instruction is that the delayed-release capsules or enteric-coated tablets must be swallowed whole; they should not be chewed, crushed, or split, as this compromises the coating essential for functional absorption. For patients unable to swallow the intact dose, the capsule's pellets can be mixed with a small amount of soft food or water for immediate consumption. Dosing modifications are specified for certain populations; for instance, a dose of 10 mg once daily is recommended for some maintenance regimens in cases of severe hepatic impairment. Pediatric use is allowed, with doses determined based on the child's weight.

Research Evidence / Overview of Studies

The Drug's Evaluation in Osteoarthritis

Research has explored the drug as a long-term management option in knee osteoarthritis. Evidence gathered from two key Phase 3 trials and one meta-analysis has been evaluated for its effects on joint function and pain in individuals with knee osteoarthritis.

• Trial 1 (N=500, RCT, 12 months): This study focused on patients with mild-to-moderate knee osteoarthritis. The primary outcome was a change in the WOMAC score (a measure of pain, stiffness, and physical function). The findings suggested a statistically significant difference in the primary endpoint measures compared to the placebo group.
• Trial 2 (N=350, Open-label, 24 months): This longer-term study tracked adherence and side effects. The side effect profile was reported as generally low, and adverse events were not frequently reported by most participants over the two-year period.
• Meta-Analysis (2023): This review combined data from 15 studies across various countries, examining the drug's short-term effects (up to 6 months). The analysis concluded that a difference in self-reported pain scores was observed between the treatment arm and the control group.

Combination Therapy Studies

Studies evaluated whether the combination of this drug with a standard non-steroidal anti-inflammatory drug (NSAID) affected mobility differently than monotherapy.

• Study A (N=200, 6 months): This trial specifically measured the time taken to complete a 50-foot walk test. The combination group findings suggested a difference in pain levels and an outcome difference in the 50-foot walk test compared to the group receiving the NSAID alone.
• Study B (N=150, Pharmacokinetics): This study focused on drug-drug interaction and absorption profiles. Studies evaluated taking the medication with a meal to explore its effect on absorption.

Patient Suitability and Contraindications

This section is strictly for informational summary based on trial findings and is not a substitute for professional medical guidance.

• Renal Impairment: Studies found that this drug was not evaluated or was excluded in people with severe kidney impairment due to a potential for accumulation of metabolites, and safety data is therefore limited.
• Hepatic Impairment: The drug was evaluated in patients with mild-to-moderate hepatic impairment, where side-effect profiles were comparable to other cohorts, and the dosages studied were consistent with the standard dosage protocol.
• Elderly Patients: Studies in older adults (aged 65+) found no evidence to suggest a separate dosage regimen was required, and adverse event reporting was similar to that of the younger adult cohort.

Key Studies & References

1. Safety and efficacy of retreatment with a bioengineered hyaluronate for painful osteoarthritis of the knee: results of the open-label Extension Study of the FLEXX Trial
2. Sustained Acoustic Medicine Combined with A Diclofenac Ultrasound Coupling Patch for the Rapid Symptomatic Relief of Knee Osteoarthritis: Multi-Site Clinical Efficacy Study
3. NCT05489614: A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment

Common questions about Ulcezol (FAQ)

---

Q: What is the primary substance in Ulcezol?

The primary active ingredient in Ulcezol is Epithelinum B-4, which is classified as a selective proton pump inhibitor. According to the official product information, this substance works by reducing the amount of acid produced in the stomach. This action helps to allow ulcers to heal and prevent new ones from forming.

Q: What is Ulcezol used to treat?

Official regulatory documents state that Ulcezol is used to treat conditions caused by excess stomach acid. These include the treatment of duodenal and gastric ulcers, as well as gastroesophageal reflux disease (GERD). Studies and official information also indicate its use in treating pathological hypersecretory conditions.

Q: How long does it take for Ulcezol to start working?

According to the official product information, the reduction in stomach acid production typically begins shortly after taking Ulcezol. However, the full therapeutic effect, such as the healing of ulcers, may take several days or weeks of consistent use. It is important to follow the treatment course as prescribed by a healthcare provider.

Q: Can I stop taking Ulcezol as soon as I feel better?

Regulatory documents emphasize that the full course of treatment with Ulcezol, as prescribed, should be completed. Stopping the medication too soon, even if symptoms improve, may lead to the return of the underlying condition. Any change to the treatment schedule should be discussed with a healthcare provider.

Q: Does Ulcezol cause weight changes (gain or loss)?

Studies and official product information indicate that significant changes in weight are not commonly listed as a primary side effect of Ulcezol. While all medications have the potential for various effects, weight fluctuation is generally considered a rare or non-listed adverse event for this specific drug. Unexpected weight changes, if experienced, should be discussed with a healthcare provider.

Q: Is Ulcezol safe for long-term use?

According to official information, Ulcezol is considered safe for prescribed short-term use. For patients requiring long-term treatment (over one year), periodic monitoring by a healthcare professional may be recommended. The decision for long-term use should be made by a healthcare provider, who will guide and review the treatment.

Q: What should I do if I miss a dose of Ulcezol?

Official product information provides specific instructions for missed doses, which typically involve taking the dose when remembered unless it is almost time for the next dose. It is generally advised not to take a double dose to make up for the missed one. These specific guidelines should be reviewed in the official leaflet provided with the medication.

Q: Can I crush or chew Ulcezol tablets?

Official product labeling generally advises against crushing or chewing Ulcezol tablets. This medication is often formulated with an enteric coating, meaning it is designed to dissolve properly in the intestine rather than the stomach. Altering the tablet may reduce its effectiveness; therefore, the tablets are generally intended to be swallowed whole.

How to Store and Dispose of Ulcezol?

The storage and disposal of Ulcezol (Omeprazole) must follow official regulatory requirements to maintain product stability and ensure public safety.

Storage Conditions

Ulcezol must be stored at Controlled Room Temperature, typically 15 C to 30 C (59 F to 86 F), and be protected from light and moisture. The medicine should be kept in its original container and be tightly closed. For bottle presentations, a limited in-use shelf life (e.g., 100 days) may apply after first opening. All forms of the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Ulcezol should be disposed of by following local regulations. The preferred method is utilizing an official drug take-back program. If a take-back program is unavailable, the medicine may be disposed of in the household trash after mixing it with an unappealing substance and sealing it in a container.